JP7335870B2 - 医薬剤形 - Google Patents

医薬剤形 Download PDF

Info

Publication number
JP7335870B2
JP7335870B2 JP2020512436A JP2020512436A JP7335870B2 JP 7335870 B2 JP7335870 B2 JP 7335870B2 JP 2020512436 A JP2020512436 A JP 2020512436A JP 2020512436 A JP2020512436 A JP 2020512436A JP 7335870 B2 JP7335870 B2 JP 7335870B2
Authority
JP
Japan
Prior art keywords
sustained release
matrix formulation
release matrix
dosage form
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532533A5 (enExample
JP2020532533A (ja
Inventor
アクジャ，オズギュル
マニオン，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of JP2020532533A publication Critical patent/JP2020532533A/ja
Publication of JP2020532533A5 publication Critical patent/JP2020532533A5/ja
Application granted granted Critical
Publication of JP7335870B2 publication Critical patent/JP7335870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020512436A 2017-08-31 2018-08-30 医薬剤形 Active JP7335870B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762552521P 2017-08-31 2017-08-31
US62/552,521 2017-08-31
PCT/US2018/048904 WO2019046611A1 (en) 2017-08-31 2018-08-30 PHARMACEUTICAL DOSAGE FORMS

Publications (3)

Publication Number Publication Date
JP2020532533A JP2020532533A (ja) 2020-11-12
JP2020532533A5 JP2020532533A5 (enExample) 2021-10-07
JP7335870B2 true JP7335870B2 (ja) 2023-08-30

Family

ID=65526129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512436A Active JP7335870B2 (ja) 2017-08-31 2018-08-30 医薬剤形

Country Status (5)

Country Link
US (2) US11911510B2 (enExample)
EP (1) EP3675842A4 (enExample)
JP (1) JP7335870B2 (enExample)
CA (1) CA3073570C (enExample)
WO (1) WO2019046611A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526598A (ja) 1998-03-09 2003-09-09 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 制御された薬物放出のためのモノリシック錠剤
US20050255157A1 (en) 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
US20070281016A1 (en) 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
JP2010519201A (ja) 2007-02-15 2010-06-03 アモーレパシフィック コーポレイション シロスタゾールを含む制御放出製剤及びその製造方法
JP2011521927A (ja) 2008-05-30 2011-07-28 ユセベ ファルマ ソシエテ アノニム ブリバラセタムを含む医薬組成物
US20110275658A1 (en) 2008-12-31 2011-11-10 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US20120039957A1 (en) 2010-08-13 2012-02-16 Acura Pharmaceuticals, Inc. Optimized niacin compositions in pharmaceutical products
JP2014510094A (ja) 2011-03-25 2014-04-24 パーデュー、ファーマ、リミテッド、パートナーシップ 制御放出性医薬剤形

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20060099256A1 (en) 2002-11-27 2006-05-11 Price James C Microspheres and related processes and pharmaceutical compositions
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
CA2671200A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US9504656B2 (en) * 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
CA3003950C (en) * 2015-10-23 2020-05-12 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
WO2017136460A1 (en) * 2016-02-01 2017-08-10 Kashiv Pharma Llc Extended release drug formulation with overdose protection and abuse deterrence

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526598A (ja) 1998-03-09 2003-09-09 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 制御された薬物放出のためのモノリシック錠剤
US20050255157A1 (en) 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
US20070281016A1 (en) 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
JP2010519201A (ja) 2007-02-15 2010-06-03 アモーレパシフィック コーポレイション シロスタゾールを含む制御放出製剤及びその製造方法
JP2011521927A (ja) 2008-05-30 2011-07-28 ユセベ ファルマ ソシエテ アノニム ブリバラセタムを含む医薬組成物
US20110275658A1 (en) 2008-12-31 2011-11-10 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US20120039957A1 (en) 2010-08-13 2012-02-16 Acura Pharmaceuticals, Inc. Optimized niacin compositions in pharmaceutical products
JP2014510094A (ja) 2011-03-25 2014-04-24 パーデュー、ファーマ、リミテッド、パートナーシップ 制御放出性医薬剤形

Also Published As

Publication number Publication date
CA3073570A1 (en) 2019-03-07
WO2019046611A1 (en) 2019-03-07
US20240269078A1 (en) 2024-08-15
EP3675842A4 (en) 2021-05-19
US11911510B2 (en) 2024-02-27
EP3675842A1 (en) 2020-07-08
CA3073570C (en) 2025-07-08
JP2020532533A (ja) 2020-11-12
US20210077409A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP6286491B2 (ja) オピオイド鎮痛薬を含む不正改変抵抗性経口医薬剤形
WO2012131463A2 (en) Controlled release pharmaceutical dosage forms
US20250127715A1 (en) Abuse deterrent morphine sulfate dosage forms
US20250017917A1 (en) Pharmaceutical dosage forms
US20150238420A1 (en) Naloxone mono preparation and multilayer tablet
US20240269078A1 (en) Pharmaceutical dosage forms
JP7736755B2 (ja) 遅延放出ゲル化剤組成物を含む医薬組成物
US20160256451A1 (en) Dosage of naloxone
AU2016206321C1 (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
US20160256453A1 (en) Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210825

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230818

R150 Certificate of patent or registration of utility model

Ref document number: 7335870

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150